Adiponectin concentration after a body mass reduction in a group of premenopausal obese women living in Lima, Peru
DOI:
https://doi.org/10.24265/horizmed.2019.v19n2.10Keywords:
Adiponectin, Exercise, Body mass index, Weight reduction programs, Reducing dietAbstract
Objective: To investigate the changes in the plasma-circulating adiponectin concentration in 23 premenopausal obese women living in Lima after a body mass reduction as a result of an aerobic physical activity program and a low-calorie diet. Materials and methods: An analytical and quasi-experimental study was conducted in a group of obese women. In addition, another 24 women were considered as control or reference group for comparing their adiponectin concentration and other biochemical markers. The quantification of adiponectin was carried out using the ELISA test. Fasting blood glucose concentration, cholesterol, high-density lipoprotein and triglycerides levels were quantified by routine clinical analysis. Results: Before beginning the program, the control group showed high adiponectin levels (median, 8.54 µg/mL; range, 6.14 µg/ mL to 13.49 µg/mL) compared to the obesity group (median, 7.03 µg/mL; range, 3.77 µg/mL to 17.23 µg/mL). However, the difference was not statistically significant (P = 0.0563). Once the program was finished, the obesity group showed a statistically significant reduction in the body mass index (P = 5.98e-08) and abdominal circumference (P = 1.55e-08), and a statistically significant increase in the adiponectin levels (median, 8.79 µg/mL; range, 5.50 µg/mL to 19.37 µg/mL) (P = 0.0127). Conclusions: Based on the results, we conclude that the adiponectin concentration in premenopausal obese women increases when the body mass is reduced as a result of aerobic physical activity and a low-calorie diet.
Downloads
References
World Health Organization. Obesidad y Sobrepeso [Internet]; 2019. Disponible en: HYPERLINK "http://www.who.int/es/news-room/fact-sheets/detail/obesity-and-overweight" www.who.int/es/news-room/fact-sheets/detail/obesity-and-overweight
Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, Inflammation, and Prostate Cancer. J Clin Med. 2019 Feb; 8(2):E201.
Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016 Dec; 45(4):571–9.
Nimptsch K, Pischon T. Obesity Biomarkers, Metabolism and Risk of Cancer: An Epidemiological Perspective. Recent Results Cancer Res. 2016; 208:199–217.
Gandjour A. Cost-effectiveness of preventing weight gain and obesity: what we know and what we need to know. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun; 12(3):297–305.
Serafini M, Toti E. Unsustainability of Obesity: Metabolic Food Waste. Front Nutr. 2016 Oct; 3:40.
Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012 Sep; 55(9):2319–26.
Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006 May; 8(3):264–80.
Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care. 2011 Apr; 15(2):221.
Volp AC, Barbosa KB, Bressan J. Triacylglycerols and body fat mass are possible independent predictors of C3 in apparently healthy young Brazilian adults. Nutrition. 2012; 28(5):544-50.
Okauchi Y, Kishida K, Funahashi T, Noguchi M, Ogawa T, Ryo M, et al. Changes in serum adiponectin concentrations correlate with changes in BMI, waist circumference, and estimated visceral fat area in middle-aged general population. Diabetes Care. 2009 Oct; 32(10):e122.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999 Apr; 257(1):79–83.
Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017 Aug; 28(4):347–54.
Liu D, Li S, Li Z. Adiponectin: A biomarker for chronic hepatitis C?. Cytokine. 2017 Jan; 89:27–33.
Shibata R, Ouchi N, Ohashi K, Murohara T. The role of adipokines in cardiovascular disease. J Cardiol. 2017 Oct; 70(4):329–34.
Zha D, Wu X, Gao P. Adiponectin and Its Receptors in Diabetic Kidney Disease: Molecular Mechanisms and Clinical Potential. Endocrinology. 2017 Jul; 158(7):2022–34.
Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo- cytokines-induced chronic inflammation. J Cancer. 2016 Nov; 7(15):2346–59.
Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol. 2016 Apr; 8(2):93–100.
Woodward L, Akoumianakis I, Antoniades C. Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease. Br J Pharmacol. 2017 Nov; 174(22):4007–20.
Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med. 1999 Feb; 38(2):202–6.
Fang CL, Huang LH, Tsai HY, Chang HI. Dermal Lipogenesis Inhibits Adiponectin Production in Human Dermal Fibroblasts while Exogenous Adiponectin Administration Prevents against UVA-Induced Dermal Matrix Degradation in Human Skin. Int J Mol Sci. 2016 Jul; 17(7):E1129.
Salman B, Yilmaz TU, Tezcaner T, Demir EO, Pasaoglu OT. Exogenous recombinant adiponectin improves survival in experimental abdominal sepsis. Balkan Med J. 2014 Sep; 31(3):244–8.
Abou-Samra M, Boursereau R, Lecompte S, Noel L, Brichard SM. Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy. Am J Pathol. 2017 Jul; 187(7):1577–85.
Ng RC, Chan KH. Potential Neuroprotective Effects of Adiponectin in Alzheimer’s Disease. Int J Mol Sci. 2017 Mar; 18(3):E592.
Ackerman SE, Blackburn OA, Marchildon F, Cohen P. Insights into the Link Between Obesity and Cancer. Curr Obes Rep. 2017 Jun; 6(2):195–203.
Francisco C, Neves JS, Falcao-Pires I, Leite-Moreira A. Can Adiponectin Help us to Target Diastolic Dysfunction?. Cardiovasc Drugs Ther. 2016 Dec; 30(6):635–44.
R Core Team. A language and environment for statistical computing [Internet]; 2018. Disponible en: https://www.r-project.org/
R Studio Team. Integrated Development for R [Internet]; 2015. Disponible en: http://www.rstudio.com/
Abranches MV, Oliveira FCE, Conceicao LL, Peluzio MD. Obesity and diabetes: the link between adipose tissue dysfunction and glucose homeostasis. Nutr Res Rev. 2015 Dec; 28(2):121–32.
Ghantous CM, Azrak Z, Hanache S, Abou-Kheir W, Zeidan A. Differential Role of Leptin and Adiponectin in Cardiovascular System. Int J Endocrinol. 2015; 2015:534320.
Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012 Feb; 165(3):574–90.
Kontny E, Janicka I, Skalska U, Maslinski W. The effect of multimeric adiponectin isoforms and leptin on the function of rheumatoid fibroblast-like synoviocytes. Scand J Rheumatol. 2015; 44(5):363–8.
Ford ND, Patel SA, Narayan KM. Obesity in Low-and Middle- Income Countries: Burden, Drivers, and Emerging Challenges. Annu Rev Public Health. 2017 Mar; 38:145–64.
Goto A, Noda M, Goto M, Yasuda K, Mizoue T, Yamaji T, et al. Plasma adiponectin levels, ADIPOQ variants, and incidence of type 2 diabetes: A nested case-control study. Diabetes Res Clin Pract. 2017 May; 127:254–64.
Ntzouvani A, Fragopoulou E, Panagiotakos D, Pitsavos C, Antonopoulou S. Reduced circulating adiponectin levels are associated with the metabolic syndrome independently of obesity, lipid indices and serum insulin levels: a cross- sectional study. Lipids Health Dis. 2016; 15(1):140.
Lee S, Kwak HB. Role of adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil. 2014 Apr; 10(2):54–9.
Hebbard L, Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab. 2014 Jan; 28(1):59–69.
Mendoza-Azpur G, Castro C, Pena L, Guerrero ME, De La Rosa M, Mendes C, et al. Adiponectin, leptin and TNF- α serum levels in obese and normal weight Peruvian adults with and without chronic periodontitis. J Clin Exp Dent. 2015 Jul; 7(3):e380-6.
Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012 Sep; 24(3):69–71.
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
